SCHEMBL10085582

SCHEMBL10085582

COC(=O)Nn1c(=O)[nH]c2ccc(C)cc2c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 7/20 0.44
KDM4E B2RXH2 5/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.44
GLA P06280 1/20 0.44
DAO P14920 1/20 0.43
NR4A2 P43354 1/20 0.43
ERCC1 P07992 1/20 0.42
DNASE1 P24855 1/20 0.42
FEN1 P39748 1/20 0.42
ERCC4 Q92889 1/20 0.42
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.41
PKM P14618 1/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10084842 0.76 KDM4E (0.42) ALDH1A1KDM4EKMT2AGAAMEN1
SCHEMBL10084475 0.76 HSD17B10 (0.47) ALDH1A1KDM4EKMT2AGAAMEN1
SCHEMBL10084835 0.75 ALDH1A1 (0.44) ALDH1A1KDM4EKMT2AGAAMEN1
SCHEMBL10085094 0.73 POLB (0.46) ALDH1A1KDM4EKMT2AGAAMEN1
SCHEMBL8215674 0.72 ADORA3 (0.61) ALDH1A1KDM4EKMT2AGAAMEN1
SCHEMBL6405730 0.72 TP53 (0.47) ALDH1A1KDM4EHPGDTP53SMN1; SMN2
SCHEMBL10085593 0.71 ALDH1A1 (0.72) ALDH1A1KDM4EKMT2AGAAMEN1
SCHEMBL10084481 0.70 KDM4E (0.50) ALDH1A1KDM4EKMT2AGAAMEN1
SCHEMBL8133826 0.70 KDM4E (0.45) ALDH1A1KDM4EKMT2AGAAMEN1
SCHEMBL10085091 0.70 POLB (0.48) L3MBTL1ALDH1A1KDM4EKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 L3MBTL1 2551/4885ALDH1A1 3536/4885KDM4E 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.